AMD Announces New HistoScanning(TM) Research

WATERLOO, Belgium--(BUSINESS WIRE)--Advanced Medical Diagnostics SA/NV (AMD), a privately held company that has developed HistoScanning™, today outlined its activities at the European Association of Urology Meeting (EAU) that is taking place in Vienna from the 18^th to the 22^nd March. HistoScanning™ is a Tissue Characterisation modality based on raw ultrasound data. HistoScanning™ provides additional and meaningful information for better management of cancer patients by providing visual reassurance for decision making.

“Ultrasound spectral interrogation of histological grade in prostate cancer using prostate HistoScanning™”

Two pieces of Prostate HistoScanning™ research have been accepted for presentation at the EAU; an update on the multicentre Prostate HistoScanning™ study (PHS-02) and early results of investigations into Prostate HistoScanning™’s ability to predict the Gleason Score of differentiated prostate tissue. PDF copies of these posters will be available for distribution after presentation at the EAU.

AMD’s booth will feature Prostate HistoScanning™, a unique Tissue Characterisation application to support decision making. A special study area will give visitors to the booth an opportunity to explore clinical case studies and study the clinical trial data.

On the 19^th March in Poster Session 2 “Prostate Cancer Screening” the latest results of the multi-centre PHS-02 study will be presented by Prof. Mark Emberton of UCLH “Evaluation of HistoScanning™ for the detection, location and volume estimation of prostate cancer: Results of open phase of the PHS-02 study”. On the 21^st March Poster Session 80 “Prostate cancer: Prognostics and treatment” Miss Simmons of UCLH will present “Ultrasound spectral interrogation of histological grade in prostate cancer using prostate HistoScanning™”.

English, Dutch, French or German speaking technical specialists will be available in the study area on the booth to discuss case studies and clinical evidence with visitors. As well as the two new studies presented at the EAU visitors will be able to review and discuss data on more than 350 patients reported by centres across Europe and the USA.

All the HistoScanning™ workstation on the EAU booth will be equipped with the recently launched Prostate HistoScanning™ Version 2.2 software. This software version offers a range of new analysis and reporting tools which will further support HistoScanning™ users and researchers.

For a full Prostate HistoScanning™ press pack please contact us at media@histoscanning.com .

In its current configuration Prostate HistoScanning™ sources the required raw ultrasound data from specific ultrasound systems and transducers manufactured by BK Medical, a leader in this niche of the Prostate Cancer market. AMD and BK Medical will be sharing a booth at the EAU (Booth number X89).

Prostate HistoScanning™, available in Europe, supports the diagnosis and management of prostate cancer. HistoScanning products for breast, ovaries, and thyroid are in development.

Dror Nir, CEO of AMD, commented, “We are working to ensure that the HistoScanning™ Tissue Characterisation modality is adopted as widely as possible. Our scientific and commercial activities at the EAU are designed to share knowledge and experience of Prostate HistoScanning™ as widely as possible in the urology community”.

In the first 3 months of 2011 the company made five new Prostate HistoScanning™ installations in Germany and Austria, bringing the total in this region to 18 centres that use HistoScanning™ on a commercial basis. There are currently 30 centres in Europe offering examinations with HistoScanning™ and performing clinical studies with Prostate HistoScanning™.

Supporting imagery for the HistoScanning™ workstation and applications is available for download at http://www.histoscanning.com/newsroom/media-coverage-and-library/. Please insert the following copyright statement when imagery is used "Imagery courtesy of Advanced Medical Diagnostics” at any occurrence. The copyright notice and terms of use can be found at http://www.histoscanning.com/copyright-notice/ and http://www.histoscanning.com/terms-of-use/.

Advanced Medical Diagnostics SA/NV:

Advanced Medical Diagnostics is a privately held company based in Waterloo, Belgium. The company is dedicated to improve cancer patient management in a clinically meaningful and cost effective manner. A dynamic and culturally diverse team of 30 experienced scientists, engineers and business professionals is committed to bringing HistoScanning™ to medical specialists and their patients around the world.

HistoScanning™ is a trademark of Advanced Medical Diagnostics SA/NV, Waterloo, Belgium